Intracisternal administration of glibenclamide or 5-hydroxydecanoate does not reverse the neuroprotective effect of ketogenic diet against ischemic brain injury-induced neurodegeneration.
OBJECTIVE
To investigate the role of ATP-sensitive potassium (K(ATP)) channels in the neuroprotective effects of a ketogenic diet against cardiac arrest-induced cerebral ischemic brain injury-induced neurodegeneration.


METHODS
Male Sprague Dawley rats were randomly divided into three groups and were fed with a ketogenic diet for 25 days before being subjected to a cardiac arrest-induced cerebral ischemia for 8 minutes 30 seconds. Four hours before cardiac arrest-induced cerebral ischemia, one group was intracisternally injected with glibenclamide, a plasma membrane K(ATP) channel blocker. The second group was injected with 5-hydroxydecanoate, a mitochondrial K(ATP) channel blocker. The third group was without the pre-treatment with K(ATP) channel antagonist. Nine days after the cardiac arrest, rats were sacrificed. Fluoro-jade (FJ) staining was used to evaluate cerebral ischemic neurodegeneration in the rat brain sections.


RESULTS
The number of FJ-positive degenerating neurons in the CA1 area of the hippocampus, the cerebellum and the thalamic reticular nucleus of the ketogenic diet-fed rats with or without glibenclamide or 5-hydroxydecanoate pre-treatment before cardiac arrest-induced cerebral ischemia is zero.


CONCLUSIONS
The results suggest that K(ATP) channels do not play a significant role in the neuroprotective effects of the ketogenic diet against cardiac arrest-induced cerebral ischemic injury-induced neurodegeneration.
Tai
K-K
KK
Long Beach Memorial Medical Center, Long Beach, CA 90806, USA. kktai@yahoo.com
Pham
L
L
Truong
D D
DD
D000818:Animals; D002545:Brain Ischemia / Q000188:drug therapy / Q000209:etiology / Q000473:pathology*; D003652:Decanoic Acids / Q000008:administration & dosage*; D055423:Diet, Ketogenic; D005452:Fluoresceins; D005905:Glyburide / Q000008:administration & dosage*; D006323:Heart Arrest / Q000150:complications; D006880:Hydroxy Acids / Q000008:administration & dosage*; D054086:KATP Channels / Q000037:antagonists & inhibitors*; D008297:Male; D009410:Nerve Degeneration / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D009930:Organic Chemicals; D026902:Potassium Channel Blockers / Q000008:administration & dosage*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley
D003652:Decanoic Acids; D005452:Fluoresceins; D006880:Hydroxy Acids; D054086:KATP Channels; D009930:Organic Chemicals; D026902:Potassium Channel Blockers; C435731:fluoro jade; C052853:5-hydroxydecanoic acid; D005905:Glyburide